Topical brimonidine tartrate as a novel treatment for facial erythema of rosacea and acne erythema. Issue 2 (May 2016)
- Record Type:
- Journal Article
- Title:
- Topical brimonidine tartrate as a novel treatment for facial erythema of rosacea and acne erythema. Issue 2 (May 2016)
- Main Title:
- Topical brimonidine tartrate as a novel treatment for facial erythema of rosacea and acne erythema
- Authors:
- Genedy, Rasha M.
- Abstract:
- Abstract : Background: Facial erythema is often observed in almost all subtypes of rosacea and may complicate acne vulgaris. It presents a significant therapeutic challenge. There are many topical treatments available for rosacea and acne vulgaris, and yet none of them directly targets the erythematous component of these two diseases. Brimonidine, a highly selective α2 -adrenergic receptor agonist, can cause constriction of peripheral vasculature. Objective: To evaluate the efficacy and safety of topical brimonidine tartrate in the treatment of erythema of rosacea and postacne erythema. Patients and methods: For 30 patients with rosacea and 30 patients with postacne erythema, topical brimonidine tartrate 0.2% solution was applied twice daily for 4 weeks. Both groups were followed up for 4 weeks after stopping the treatment. Erythema was assessed every 2 weeks during the treatment phase and at the end of the follow-up phase. Results: Erythema score gradually decreased during the 4 weeks of treatment with brimonidine in both groups. This improvement was statistically significant at the end of the treatment phase. At the end of the follow-up period, erythema was still significantly lower than that at the time of enrollment in both groups. The improvement was significantly higher in the acne group than in the rosacea group at the end of both the treatment phase and the follow-up period. Conclusion: Topical brimonidine is considered both effective and safe in the treatment ofAbstract : Background: Facial erythema is often observed in almost all subtypes of rosacea and may complicate acne vulgaris. It presents a significant therapeutic challenge. There are many topical treatments available for rosacea and acne vulgaris, and yet none of them directly targets the erythematous component of these two diseases. Brimonidine, a highly selective α2 -adrenergic receptor agonist, can cause constriction of peripheral vasculature. Objective: To evaluate the efficacy and safety of topical brimonidine tartrate in the treatment of erythema of rosacea and postacne erythema. Patients and methods: For 30 patients with rosacea and 30 patients with postacne erythema, topical brimonidine tartrate 0.2% solution was applied twice daily for 4 weeks. Both groups were followed up for 4 weeks after stopping the treatment. Erythema was assessed every 2 weeks during the treatment phase and at the end of the follow-up phase. Results: Erythema score gradually decreased during the 4 weeks of treatment with brimonidine in both groups. This improvement was statistically significant at the end of the treatment phase. At the end of the follow-up period, erythema was still significantly lower than that at the time of enrollment in both groups. The improvement was significantly higher in the acne group than in the rosacea group at the end of both the treatment phase and the follow-up period. Conclusion: Topical brimonidine is considered both effective and safe in the treatment of postacne erythema as well as rosacea erythema. It could be considered as a therapeutic alternative to laser therapy for patients with the above-mentioned diseases. … (more)
- Is Part Of:
- Journal of the Egyptian Women's Dermatologic Society. Volume 13:Issue 2(2016:May)
- Journal:
- Journal of the Egyptian Women's Dermatologic Society
- Issue:
- Volume 13:Issue 2(2016:May)
- Issue Display:
- Volume 13, Issue 2 (2016)
- Year:
- 2016
- Volume:
- 13
- Issue:
- 2
- Issue Sort Value:
- 2016-0013-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-05
- Subjects:
- brimonidine -- post acne erythema -- rosacea
Dermatology -- Periodicals
Dermatology
Periodicals
616.5005 - Journal URLs:
- http://cufts2.lib.sfu.ca/CJDB/BVAS/journal/267143 ↗
http://journals.lww.com/jewds/pages/default.aspx ↗
http://www.jewds.eg.net/index.htm ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/01.EWX.0000483162.96767.73 ↗
- Languages:
- English
- ISSNs:
- 1687-1537
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19228.xml